Kane Biotech Announces New Private Placement Offering

Executive Summary

• Kane Biotech Inc. announced a non‑brokered private placement of up to 16 million common shares at $0.05 per share, targeting gross proceeds of up to $800,000.
• Net proceeds will be used for working capital and general corporate purposes; the offering is expected to close around December 17, 2025, subject to TSX Venture Exchange approval.
• Shares issued will be subject to a hold period of four months and one day from issuance.

Key Details

• Offering Size: Up to 16 million common shares.
• Price per Share: $0.05.
• Gross Proceeds Target: Up to $800,000.
• Use of Proceeds: Working capital and general corporate purposes.
• Closing Date: Expected on or about December 17, 2025.
• Hold Period: Four months plus one day from the date of issuance for all shares issued in the placement.
• Eligibility: Certain insiders may participate; offering is non‑brokered and private.
• Regulatory Conditions: Subject to receipt of all necessary approvals, including TSX Venture Exchange approval.
• Legal Disclaimer: Offering not registered under U.S. securities laws; cannot be offered or sold in the United States or to U.S. persons unless exempt or registered.

Notable Quotes

(No executive quotes were included in the release.)